MX2021009851A - Formulacion de anticuerpos terapeuticos. - Google Patents

Formulacion de anticuerpos terapeuticos.

Info

Publication number
MX2021009851A
MX2021009851A MX2021009851A MX2021009851A MX2021009851A MX 2021009851 A MX2021009851 A MX 2021009851A MX 2021009851 A MX2021009851 A MX 2021009851A MX 2021009851 A MX2021009851 A MX 2021009851A MX 2021009851 A MX2021009851 A MX 2021009851A
Authority
MX
Mexico
Prior art keywords
therapeutic antibody
antibody formulation
pharmaceutical formulations
aqueous pharmaceutical
stable aqueous
Prior art date
Application number
MX2021009851A
Other languages
English (en)
Inventor
Vincent John Corvari
Karthik Pisupati
Galen Huaiqiu Shi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2021009851A publication Critical patent/MX2021009851A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

Formulaciones farmacéuticas acuosas estables para anticuerpos terapéuticos y métodos de uso de dichas formulaciones farmacéuticas acuosas estables.
MX2021009851A 2019-02-18 2020-02-11 Formulacion de anticuerpos terapeuticos. MX2021009851A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962807006P 2019-02-18 2019-02-18
US201962880846P 2019-07-31 2019-07-31
US201962947198P 2019-12-12 2019-12-12
PCT/US2020/017594 WO2020172002A1 (en) 2019-02-18 2020-02-11 Therapeutic antibody formulation

Publications (1)

Publication Number Publication Date
MX2021009851A true MX2021009851A (es) 2021-09-10

Family

ID=72040829

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009851A MX2021009851A (es) 2019-02-18 2020-02-11 Formulacion de anticuerpos terapeuticos.

Country Status (20)

Country Link
US (2) US11634485B2 (es)
EP (1) EP3927729A4 (es)
JP (2) JP7266108B2 (es)
KR (1) KR20210114989A (es)
CN (1) CN113474360A (es)
AU (2) AU2020225202B2 (es)
CA (1) CA3129901A1 (es)
CL (1) CL2021002182A1 (es)
CO (1) CO2021010697A2 (es)
CR (1) CR20210435A (es)
DO (1) DOP2021000170A (es)
EC (1) ECSP21060917A (es)
IL (1) IL285134A (es)
JO (1) JOP20210229A1 (es)
MA (1) MA55033A (es)
MX (1) MX2021009851A (es)
PE (1) PE20212185A1 (es)
SG (1) SG11202108627SA (es)
UA (1) UA128098C2 (es)
WO (1) WO2020172002A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN117083295A (zh) * 2021-01-08 2023-11-17 拉尼尔生物治疗公司 Il-17a的中和抗体、其融合蛋白及其应用
CN116874596B (zh) * 2023-09-06 2023-11-24 南京佰抗生物科技有限公司 抗S100β蛋白的单克隆抗体及其制备方法和应用

Family Cites Families (359)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
DK1475101T3 (da) 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US7135180B2 (en) 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2011226771B2 (en) 2002-06-14 2012-10-04 Medimmune, Llc Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20060246060A1 (en) 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7055598B2 (en) 2002-08-26 2006-06-06 Halliburton Energy Services, Inc. Fluid flow control device and method for use of same
WO2004019860A2 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
WO2004055164A2 (en) 2002-12-13 2004-07-01 Abgenix, Inc. System and method for stabilizing antibodies with histidine
AU2003291527A1 (en) 2002-12-31 2004-07-29 Nektar Therapeutics Antibody-containing particles and compositions
US20040208869A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
LT2335725T (lt) 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
JP2007536896A (ja) 2003-06-05 2007-12-20 ジェネンテック・インコーポレーテッド Ｂｌｙｓアンタゴニストとその用途
ES2721548T3 (es) 2003-08-12 2019-08-01 Lilly Co Eli Aparato de dispensado de medicamentos con roscas de tornillo triples para una ventaja mecánica
CA2540848C (en) 2003-10-01 2012-12-11 Kyowa Hakko Kogyo Co., Ltd. Method for stabilizing antibody and stabilized solution-type antibody preparation
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
AR046774A1 (es) 2003-12-24 2005-12-21 Boehringer Ingelheim Pharma Formulacion liofilizada de conjugados de anticuerpos
WO2005063291A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
NZ549099A (en) 2004-03-30 2010-05-28 Lilly Co Eli Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005322410B2 (en) 2004-11-30 2011-11-10 Amgen Fremont Inc. Antibodies directed to GPNMB and uses thereof
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
CN101166763B (zh) 2005-04-18 2012-09-19 伊达研究和发展有限公司 稳定的抗乙肝病毒(hbv)抗体配制剂
EP3260465A1 (en) 2005-06-07 2017-12-27 ESBATech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting tnf-alpha
WO2006138181A2 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
CN101287761A (zh) 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
KR101566393B1 (ko) 2005-08-03 2015-11-05 이뮤노젠 아이엔씨 면역접합체 제형
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
DOP2005000210A (es) 2005-10-19 2006-04-30 Genentech Inc Antibony formulations
US20070172520A1 (en) 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
BRPI0618893A2 (pt) 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
PT1963368E (pt) * 2005-12-13 2012-09-14 Lilly Co Eli Anticorpos anti-il-17
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
MX2008008621A (es) 2005-12-29 2008-11-27 Centocor Inc Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EA200870264A1 (ru) 2006-02-15 2009-02-27 Имклоун Системз Инкорпорейтед Композиция антител
WO2007124082A2 (en) 2006-04-21 2007-11-01 Amgen, Inc. Buffering agents for biopharmaceutical formulations
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP2029163A4 (en) 2006-06-14 2010-08-11 Imclone Llc LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES
WO2008029908A1 (fr) 2006-09-07 2008-03-13 Kyowa Hakko Kirin Co., Ltd. Préparation pharmaceutique lyophilisée stable comprenant un anticorps
EP2066350A4 (en) 2006-09-25 2010-04-07 Medimmune Llc STABILIZED ANTIBODY FORMULATIONS AND THEIR USES
US20080112953A1 (en) 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
ES2925992T3 (es) 2006-10-20 2022-10-20 Amgen Inc Formulaciones estables de polipéptidos
DE102006053375A1 (de) 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
US20080213282A1 (en) 2006-12-21 2008-09-04 Jaby Jacob Formulations
MX2009007406A (es) 2007-01-09 2010-01-25 Wyeth Corp Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
CN105037549B (zh) 2007-01-11 2018-09-28 诺和诺德公司 抗-kir抗体、制剂及其应用
UA96473C2 (ru) 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
TW200909005A (en) * 2007-06-14 2009-03-01 Elan Pharm Inc Lyophilized immunoglobulin formulations and methods of preparation
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
MX354100B (es) 2007-11-30 2018-02-13 Abbvie Biotechnology Ltd Star Formulaciones de proteinas y metodos para elaborarlas.
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
CA2726837A1 (en) 2008-06-26 2009-12-30 Wyeth Llc Lyophilization cycle robustness strategy
WO2010017296A1 (en) 2008-08-05 2010-02-11 Wyeth Lyophilization above collapse
MX2011002159A (es) 2008-08-27 2011-03-29 Schering Corp Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
AU2009294680A1 (en) 2008-09-19 2010-03-25 F. Hoffmann-La Roche Ag Novel antibody formulation
ES2658596T3 (es) 2008-09-19 2018-03-12 Pfizer Inc. Formulación líquida estable de anticuerpos
WO2010042705A1 (en) 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
CN102281902B (zh) 2008-11-17 2013-11-13 弗·哈夫曼-拉罗切有限公司 用于减少大分子在生理条件下聚集的方法和制剂
WO2010057107A1 (en) 2008-11-17 2010-05-20 Genentech, Inc. Method and formulation for reducing aggregation of a macromolecule under physiological conditions
WO2010059787A1 (en) 2008-11-20 2010-05-27 Genentech, Inc. Therapeutic protein formulations
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
EP2350649A4 (en) 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
CA2744510A1 (en) * 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
RU2015132478A (ru) * 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
AU2010221099A1 (en) 2009-03-06 2011-09-22 Medimmune, Llc Humanized anti-CD19 antibody formulations
EP2439533B1 (en) 2009-03-31 2017-08-02 DENKA SEIKEN Co., Ltd. Immunoassay method and reagent therefor
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
KR20120027031A (ko) 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
WO2010148321A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Slow dissolution method for reconstitution of lyophilized material
WO2011008770A2 (en) 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
PT3721904T (pt) 2009-11-20 2021-11-15 Biocon Ltd Formulações de anticorpo t1h
JP2013515754A (ja) 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規な抗体製剤
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
LT2523688T (lt) 2010-01-15 2018-03-12 Kirin-Amgen, Inc. Antikūno kompozicija ir terapiniai režimai
NZ602685A (en) 2010-03-01 2014-10-31 Cytodyn Inc Concentrated protein formulations and uses thereof
HUE025794T2 (en) 2010-03-01 2016-05-30 Lilly Co Eli Automatic injection device with delay mechanism and double-acting pressure element
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
BR112012023895A2 (pt) 2010-03-17 2016-11-29 Abbott Res Bv composições de anti-fator de crescimento do nervo (ngf)
CN102946858B (zh) 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
CN102946903B (zh) 2010-05-14 2014-11-26 安进公司 高浓度抗体制剂
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
AU2011274363A1 (en) 2010-07-02 2013-01-24 Medimmune, Llc Antibody formulations
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
FR2962650B1 (fr) 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
WO2012037430A1 (en) 2010-09-17 2012-03-22 Abbott Laboratories Raman spectroscopy for bioprocess operations
CA2813587C (en) 2010-10-06 2019-01-15 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
ES2733712T3 (es) 2010-11-05 2019-12-02 Novartis Ag Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17
KR101841527B1 (ko) * 2010-11-11 2018-03-23 애브비 바이오테크놀로지 리미티드 개선된 고농도 항－ＴＮＦα 항체 액체 제형
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2648750B1 (en) 2010-12-10 2017-01-25 Novartis AG Antibody formulation
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EP2500035A1 (en) 2011-03-15 2012-09-19 Icon Genetics GmbH Pharmaceutical formulation containing immunglobulin
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
LT2691112T (lt) 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
TW201306866A (zh) 2011-06-30 2013-02-16 Genentech Inc 抗－ｃ－ｍｅｔ抗體調配物
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
KR101994809B1 (ko) 2011-10-31 2019-07-01 제넨테크, 인크. 항체 제제
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
IN2014MN01488A (es) 2011-12-23 2015-04-17 Mersana Therapeutics Inc
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
EP3974018A1 (en) 2012-03-07 2022-03-30 DEKA Products Limited Partnership Infusion pump assembly
PE20142275A1 (es) * 2012-03-07 2015-01-08 Lilly Co Eli Formulacion de anticuerpo il-17
CN104159614A (zh) 2012-03-07 2014-11-19 卡迪拉保健有限公司 TNF-α抗体的药物制剂
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
EP3427721A1 (en) 2012-05-18 2019-01-16 Genentech, Inc. High-concentration monoclonal antibody formulations
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
US20140227250A1 (en) 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CA3153799A1 (en) * 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
EP2914626A2 (en) 2012-11-01 2015-09-09 Abbvie Inc. Stable dual variable domain immunoglobulin protein formulations
EP2931311A4 (en) 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
SG11201504897YA (en) 2012-12-21 2015-07-30 Glenmark Pharmaceuticals Sa Anti her2 antibody formulation
CN105209068A (zh) 2013-02-07 2015-12-30 免疫医疗公司 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
CA2904713A1 (en) 2013-03-11 2014-10-09 Amgen Inc. Protein formulations comprising darbepoetin
SG10201913932VA (en) 2013-03-13 2020-03-30 Genentech Inc Antibody formulations
KR102401525B1 (ko) 2013-03-13 2022-05-24 씨젠 인크. 사이클로덱스트린 및 항체-약물 포합체 제형
JP6541581B2 (ja) 2013-03-15 2019-07-10 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 低濃度抗体製剤
US20140286969A1 (en) 2013-03-15 2014-09-25 Abbvie Inc. Anti-egfr antibody drug conjugate formulations
CA2903611C (en) 2013-03-15 2023-11-07 Takeda Gmbh Formulation of an antibody and use thereof
US9023357B2 (en) 2013-03-15 2015-05-05 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9700485B2 (en) * 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
BR112015030501A2 (pt) 2013-06-04 2017-07-25 Vyome Biosciences Pvt Ltd partículas revestidas e composições que compreendem as mesmas
AU2014283185B2 (en) 2013-06-21 2019-05-02 Innate Pharma Enzymatic conjugation of polypeptides
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
KR102651018B1 (ko) 2013-09-11 2024-03-27 이글 바이오로직스 인코퍼레이티드 점도저하제를 함유하는 액체 단백질 제형
HUE047194T2 (hu) 2013-09-27 2020-04-28 Hoffmann La Roche Anti-PDL1 antitest készítmények
SG10201803178UA (en) 2013-10-24 2018-05-30 Astrazeneca Ab Stable, aqueous antibody formulations
CN113521016A (zh) 2013-11-21 2021-10-22 根马布股份公司 抗体-药物缀合物冻干制剂
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
WO2015121318A1 (en) 2014-02-12 2015-08-20 Sanofi Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations
US20150274819A1 (en) 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
US20150291689A1 (en) 2014-03-09 2015-10-15 Abbvie, Inc. Compositions and Methods for Treating Rheumatoid Arthritis
ES2785375T3 (es) 2014-03-11 2020-10-06 Green Cross Holdings Corp Procedimiento de purificación de inmunoglobulina
KR101917197B1 (ko) 2014-03-11 2018-11-09 주식회사 녹십자홀딩스 면역글로불린의 정제방법
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CN106132439A (zh) 2014-03-31 2016-11-16 豪夫迈·罗氏有限公司 包含抗血管发生剂和ox40结合激动剂的组合疗法
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
WO2015151115A1 (en) 2014-04-02 2015-10-08 Intas Pharmaceuticals Limited Liquid pharmaceutical composition of adalimumab
JP2017512814A (ja) 2014-04-07 2017-05-25 シアトル ジェネティックス， インコーポレイテッド 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤
JP2015209384A (ja) 2014-04-24 2015-11-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 医薬製剤
EP4285930A3 (en) 2014-06-26 2024-02-28 Amgen Inc. Protein formulations
AU2015301399B2 (en) 2014-08-14 2018-11-08 Brown University Compositions for stabilizing and delivering proteins
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
JP2017527560A (ja) 2014-09-03 2017-09-21 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 安定抗ｉｌ−４ｒアルファ抗体配合物
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
JP2017532342A (ja) 2014-10-17 2017-11-02 アムジエン・インコーポレーテツド 眼療法のためのアンジオポエチン−１及びアンジオポエチン−２を対象とする抗体
SG11201702177VA (en) * 2014-10-18 2017-04-27 Pfizer Anti-il-7r antibody compositions
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
WO2016109822A1 (en) 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
WO2016120753A1 (en) 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
SG11201705484WA (en) 2015-02-09 2017-08-30 Ucb Biopharma Sprl Pharmaceutical formulation
AU2016217806A1 (en) 2015-02-13 2017-10-05 Sanofi Stable liquid formulation for monoclonal antibodies
MY188749A (en) 2015-04-17 2021-12-28 Bristol Myers Squibb Co Compositions comprising a combination of nivolumab and ipilimumab
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
EA201792527A1 (ru) * 2015-07-16 2018-06-29 Эли Лилли Энд Компани Лечение зуда
PT3337502T (pt) 2015-08-19 2020-09-23 Astrazeneca Ab Formulação anti-ifnar1 estável
CN106474470B (zh) * 2015-08-28 2020-05-22 江苏恒瑞医药股份有限公司 一种抗il-17a抗体的组合物
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
EP3352790A1 (en) 2015-09-22 2018-08-01 Pfizer Inc Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
CN106999591B (zh) 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CN106620690A (zh) 2015-10-30 2017-05-10 上海抗体药物国家工程研究中心有限公司 一种稳定的抗体制剂
WO2017075259A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody formulations
US11654046B2 (en) 2015-11-18 2023-05-23 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
WO2017095848A1 (en) 2015-11-30 2017-06-08 Medimmune, Llc Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
MX2018006875A (es) 2015-12-07 2018-11-09 Merck Patent Gmbh Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.
CN109152831A (zh) 2015-12-29 2019-01-04 安口生物公司 贝伐珠单抗的缓冲制剂
US20190284282A1 (en) 2016-01-12 2019-09-19 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition
BR112018014277A2 (pt) 2016-01-13 2018-12-18 Genmab As formulação, e, método de preparação de uma solução injetável de um axl-adc
JP6953433B2 (ja) 2016-01-26 2021-10-27 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
US20170218092A1 (en) 2016-01-28 2017-08-03 Janssen Biotech, Inc. Bispecific Anti-TNF-Alpha/IL17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their Use
AR103622A1 (es) 2016-02-05 2017-05-24 Ucb Biopharma Sprl Formulación farmaceutica
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
AU2017238651A1 (en) 2016-03-25 2018-10-04 Visterra, Inc. Formulation of antibody molecules to dengue virus
JP6992262B2 (ja) 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
US10905649B2 (en) 2016-04-12 2021-02-02 Capsular Technologies Pty Ltd Injectable composition for delivery of a biologically active agent
JP2019511531A (ja) 2016-04-13 2019-04-25 メディミューン，エルエルシー 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
CN109475508A (zh) 2016-06-07 2019-03-15 阿瑞迪思医药品股份有限责任公司 具有增强的热稳定性的含有生物活性材料的速溶薄膜的制备方法
SG11201810429UA (en) 2016-06-27 2018-12-28 Morphosys Ag Anti-cd19 antibody formulations
US11951207B2 (en) 2016-06-30 2024-04-09 Celltrion Inc. Stable liquid pharmaceutical preparation
AU2017293103A1 (en) 2016-07-05 2019-02-21 Sanofi Antibody formulations
EP3487881A1 (en) 2016-07-19 2019-05-29 Novartis AG Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
FR3056912B1 (fr) 2016-09-30 2019-12-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Procede d'inactivation virale d'une preparation d'anticorps monoclonaux
MA46466A (fr) 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
MY197672A (en) 2016-10-07 2023-07-03 Regeneron Pharma Room temperature stable lyophilized protein
AU2017380842A1 (en) 2016-12-23 2019-07-11 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
EP3563863B1 (en) 2016-12-28 2023-07-12 JCR Pharmaceuticals Co., Ltd. Lyophilized preparation
WO2018122053A1 (en) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Anti-angiopoietin-2 antibody formulation
CN108261391B (zh) 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261544B (zh) 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
AU2018207367B2 (en) 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula
TW202138007A (zh) 2017-01-17 2021-10-16 美商建南德克公司 皮下her2抗體調配物
PL3570882T3 (pl) 2017-01-19 2022-02-07 Bayer Pharma Aktiengesellschaft Nowa stabilna formulacja dla przeciwciał fxia
GB201703062D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
EP3797792A1 (en) 2017-03-01 2021-03-31 MedImmune Limited Formulations of anti-gm-csfralpha monoclonal antibody
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
AR111229A1 (es) 2017-03-06 2019-06-19 Merck Patent Ges Mit Beschraenkter Haftung Formulación acuosa de anticuerpo
WO2018169348A1 (ko) 2017-03-16 2018-09-20 주식회사 엘지화학 항-tnf 알파 항체의 액상 제제
AU2018246252A1 (en) 2017-03-29 2019-09-19 Celgene Corporation Formulations comprising PD-1 binding proteins and methods of making thereof
JPWO2018179138A1 (ja) 2017-03-29 2020-02-06 持田製薬株式会社 抗体含有液体製剤
TW201836637A (zh) 2017-03-29 2018-10-16 持田製藥股份有限公司 含有抗體之液體製劑
TWI775827B (zh) 2017-03-31 2022-09-01 日商明治製菓藥業股份有限公司 水性製劑及裝入注射器之水性製劑以及抗體蛋白去凝集劑及抗體蛋白去凝集方法
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JOP20190255A1 (ar) 2017-04-28 2019-10-27 Amgen Inc صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN110799545A (zh) 2017-07-10 2020-02-14 拜耳制药股份公司 用于男性和女性模式脱发的催乳素受体抗体
CN107400164A (zh) 2017-07-18 2017-11-28 中山和芯生物技术有限公司 一种含蔗糖的生物制品稳定剂及其制备方法和应用
WO2019018640A1 (en) 2017-07-21 2019-01-24 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
US11077059B2 (en) 2017-07-25 2021-08-03 Elektrofi, Inc. Electrospraying formation of particles including agents
EP3659586B1 (en) 2017-07-27 2023-06-21 Jiangsu Hengrui Medicine Co., Ltd. Sost antibody pharmaceutical composition and uses thereof
AU2018308930A1 (en) 2017-07-28 2020-02-06 F. Hoffmann-La Roche Ag Bispecific antibody formulation
CA3073185A1 (en) 2017-08-15 2019-02-21 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
CN110944667A (zh) 2017-08-23 2020-03-31 第一三共株式会社 抗体-药物缀合物制剂及其冻干
CN111107873A (zh) 2017-09-05 2020-05-05 默沙东公司 用于降低生物制剂粘度的化合物
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
JP2020535181A (ja) 2017-09-29 2020-12-03 ヤンセン バイオテツク，インコーポレーテツド 低用量抗体組成物を安定化する新規製剤
JP7170983B2 (ja) 2017-10-13 2022-11-15 国立大学法人大阪大学 改善された保存安定性を有するタンパク質含有液体製剤およびその製造方法
CN109745559A (zh) 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
GB201718888D0 (en) 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CA3083356A1 (en) 2017-11-29 2019-06-06 Prothena Biosciences Limited Lyophilized formulation of a monoclonal antibody against transthyretin
KR20200093628A (ko) 2017-11-30 2020-08-05 바이오-테라 솔루션즈 리미티드 Il-6 관련 질병을 치료하는 인간화항체의 액체 제제
KR20200104314A (ko) 2017-12-22 2020-09-03 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Lag-3 항체 약학 조성물 및 이의 용도
US20210047407A1 (en) 2018-02-08 2021-02-18 Amgen Inc. Low ph pharmaceutical antibody formulation
MX2020009275A (es) 2018-03-07 2021-01-08 Pfizer Composiciones de anticuerpo anti-pd-1.
US11427639B2 (en) 2018-04-02 2022-08-30 Richter Gedeon Nyrt. Antibody-containing aqueous formulation and use thereof
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
AU2019250443A1 (en) 2018-04-10 2020-10-22 Genmab A/S AXL-specific antibodies for cancer treatment
WO2019204380A1 (en) 2018-04-17 2019-10-24 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab for use of treating diseases
BR112020020390A2 (pt) 2018-04-25 2021-01-19 Medimmune Limited Formulações de anticorpos anti-pd-l1 humanos
AU2019265005A1 (en) 2018-05-10 2020-12-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
EP3794031A2 (en) 2018-05-14 2021-03-24 MedImmune Limited Antibodies against lif and dosage forms thereof
CN110538321B (zh) 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 一种cd47抗体药物组合物及其用途
JP7458998B2 (ja) 2018-06-01 2024-04-01 ラクテン・メディカル，インコーポレイテッド フタロシアニン色素コンジュゲート組成物
EP3801469A4 (en) 2018-06-07 2022-03-09 Merck Sharp & Dohme Corp. KIT OF CRITICAL REAGENTS IN THE FORM OF LYOSPHERES
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20210363233A1 (en) 2018-06-20 2021-11-25 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
JP2021528498A (ja) 2018-06-22 2021-10-21 ビオラリクス ベー．フェー． 経口投与用生物学的ポリマーの製剤
KR20210024082A (ko) 2018-06-25 2021-03-04 제이씨알 파마 가부시키가이샤 단백질 함유 수성 액제
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
SG11202012514PA (en) 2018-07-05 2021-01-28 Hangzhou Dac Biotech Co Ltd Cross-linked pyrrolobenzodiazepine dimer (pbd) derivative and its conjugates
EP3823594A1 (en) 2018-07-19 2021-05-26 Ichnos Sciences S.A. Liquid antibody formulation
EP3824904A4 (en) 2018-07-19 2021-08-25 Celltrion, Inc. STABLE LIQUID PHARMACEUTICAL PREPARATION
WO2020041532A1 (en) 2018-08-21 2020-02-27 Sf17 Therapeutics, Inc. Compositions and methods for treating progressive neurodegenerative diseases
EP3849513A1 (en) 2018-09-11 2021-07-21 Ichnos Sciences SA Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
MX2021002935A (es) 2018-09-13 2021-06-15 Hoffmann La Roche Formulacion de anticuerpos contra csf-1r.
EA202190878A1 (ru) 2018-10-05 2021-07-02 Файв Прайм Терапьютикс, Инк. Составы на основе антитела к fgfr2
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
EP3867250A4 (en) 2018-10-12 2022-08-17 Hangzhou Dac Biotech Co., Ltd. CONJUGATING LINKERS CONTAINING A 2,3-DIAMINOSUCCINYL GROUP
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
EP3870145A1 (en) 2018-10-26 2021-09-01 Amgen Inc. Formulations comprising a tris buffer and a protein
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
WO2020088346A1 (en) 2018-10-31 2020-05-07 Mycenax Biotech Inc. Aqueous pharmaceutical formulations
EP3877409A1 (en) 2018-11-06 2021-09-15 Genmab A/S Antibody formulation
EP3876978A4 (en) 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE
US20200155678A1 (en) 2018-11-21 2020-05-21 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
WO2020117373A1 (en) 2018-12-03 2020-06-11 Agensys, Inc. Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
AU2019395841A1 (en) 2018-12-14 2021-05-20 Morphosys Ag Antibody formulations
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
US20220096324A1 (en) 2019-01-25 2022-03-31 Sio2 Medical Products, Inc. Common contact surfaces for use in the manufacture, packaging, delivery, and assessment of biopharmaceutical products
CA3128264A1 (en) 2019-01-31 2020-08-06 Hangzhou Dac Biotech Co., Ltd A conjugate of an amanita toxin with branched linkers
JP2022523510A (ja) 2019-01-31 2022-04-25 エレクトロフィ，インコーポレイテッド 粒子形成及び形態構造
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
TW202102260A (zh) 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
CA3094194A1 (en) 2019-03-26 2020-09-26 Remegen Co., Ltd. Pharmaceutical formulations of her2 antibody-drug conjugate
TW202102266A (zh) 2019-04-01 2021-01-16 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
EP3947448A4 (en) 2019-04-04 2023-02-01 Janssen Biotech, Inc. METHOD FOR ADMINISTRATION OF AN ANTI-IFN-ALPHA/-OMEGA ANTIBODY
WO2020215021A1 (en) 2019-04-18 2020-10-22 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
WO2020223565A1 (en) 2019-05-01 2020-11-05 Corvidia Therapeutics, Inc. Anti-il-6 antibody formulation
WO2020233534A1 (zh) 2019-05-17 2020-11-26 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
US11827671B2 (en) 2019-05-24 2023-11-28 Sanofi Methods for treating systemic sclerosis
EP3976642A4 (en) 2019-05-28 2023-11-08 The General Hospital Corporation APOE ANTIBODIES, FUSION PROTEINS AND THEIR USES
US20220233709A1 (en) 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
CN110124030A (zh) 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
JP2022541874A (ja) 2019-06-11 2022-09-28 サイファイ エス．ピー．エー． マイクロエマルション組成物
JP2022539076A (ja) 2019-06-24 2022-09-07 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 分岐連結体を有する細胞結合分子と細胞毒性剤との共役体
US20220273796A1 (en) 2019-07-19 2022-09-01 Ichnos Sciences SA Lyophilized antibody formulation
EP3766481A1 (en) 2019-07-19 2021-01-20 Ichnos Sciences SA Liquid antibody formulation
US20210030868A1 (en) 2019-07-29 2021-02-04 Cai Gu Huang Formulation of antibody based drugs for treating lung cancer by inhalation
EP4027978A1 (en) 2019-09-13 2022-07-20 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
EP4031570A1 (en) 2019-09-20 2022-07-27 Novartis AG Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
CN110585430B (zh) 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
JP2022552152A (ja) 2019-10-02 2022-12-15 アラマブ セラピューティクス， インコーポレイテッド 抗コネキシン抗体製剤
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CN111840217B (zh) 2020-06-19 2021-04-02 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂

Also Published As

Publication number Publication date
KR20210114989A (ko) 2021-09-24
JP7266108B2 (ja) 2023-04-27
MA55033A (fr) 2021-12-29
CN113474360A (zh) 2021-10-01
US20230183334A1 (en) 2023-06-15
CL2021002182A1 (es) 2022-03-18
WO2020172002A1 (en) 2020-08-27
AU2023251529A1 (en) 2024-01-18
SG11202108627SA (en) 2021-09-29
UA128098C2 (uk) 2024-04-03
JP2023089190A (ja) 2023-06-27
DOP2021000170A (es) 2021-09-30
ECSP21060917A (es) 2021-09-30
IL285134A (en) 2021-09-30
CO2021010697A2 (es) 2021-10-29
CA3129901A1 (en) 2020-08-27
US20200262911A1 (en) 2020-08-20
AU2020225202B2 (en) 2023-10-26
CR20210435A (es) 2021-09-20
EP3927729A4 (en) 2023-10-11
JP2022520857A (ja) 2022-04-01
AU2020225202A1 (en) 2021-08-12
JOP20210229A1 (ar) 2023-01-30
EP3927729A1 (en) 2021-12-29
US11634485B2 (en) 2023-04-25
PE20212185A1 (es) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
MX2021009851A (es) Formulacion de anticuerpos terapeuticos.
MY185802A (en) Antibody formulation
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
PH12019502444A1 (en) Formulations of human anti-rankl antibodies, and methods of using the same
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MX2019013693A (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteinas de las mismas.
MX2020009275A (es) Composiciones de anticuerpo anti-pd-1.
PH12020551716A1 (en) Anti-ror antibody constructs
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
MX2021005085A (es) Formulacion de anticuerpo.
MX2017003121A (es) Formulaciones de anticuerpos.
JOP20210015A1 (ar) تركيبات مضادات fcrn وطرق استخدامها
ZA202006264B (en) Stable formulations of therapeutic antibody
EP3890778A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY CONJUGATES - MEDICINES AND METHODS OF USING THE SAME
MX2021007047A (es) Formulaciones de anticuerpos.
MX2021005910A (es) Formulacion de proteina de alta concentracion.
MX2021005015A (es) Formulaciones farmaceuticas acuosas.
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
MX2023002889A (es) Formulaciones de anticuerpos terapeuticos.
CR20200552A (es) Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
EA202191990A1 (ru) Состав терапевтического антитела